Biogen Exercises Option with Ionis to Develop and Commercialize Investigational ASO for SMA
BIIB115 is a preclinical investigational antisense oligonucleotide (ASO) that may have the potential for extended dosing intervalsBiogen paid Ionis a $60 million one-time upfront payment CAMBRIDGE, Mass. and CARLSBAD, Calif., Jan. 04,…